Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04083430

Acronym

CYF-8

Enrollment

Registered

2019-09-10

Start date

2019-10-08

Completion date

2025-12-15

Last updated

2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytotoxicity, Healthy, Yellow Fever Vaccination Reaction

Brief summary

Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination and the following licensing of these epitope-specific CD8 T cells

Detailed description

CD: cluster of differentiation YF: yellow fever

Interventions

DRUGYellow Fever Vaccine

STAMARIL, powder and solvent for suspension for injection in pre-filled syringe. After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU. Powder and solvent for suspension for injection. Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Age between 18 to 60 years * Informed consent given

Exclusion criteria

* Fever (orally \>37,5 C) on day of vaccination * Immunosuppressants * Pregnant or breast feeding * Severe immunodeficiency * Known thymus dysfunction * Allergy against egg * Known haemophilia * Previous severe reaction to vaccine * Not willing to use anticonceptives 4 weeks after vaccination

Design outcomes

Primary

Measure	Time frame	Description
Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 21(+/-3) days after vaccination with YF-17D	21(+/-3) days	Measured by flow cytometry
Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 100 (+/- 40) days after vaccination with YF-17D	100 (+/- 40) days	Measured by flow cytometry

Secondary

Measure	Time frame	Description
% of patients with novel yellow fever vaccine epitopes according to HLA-type defining optimal timepoint for T cell licensing	21(+/-3) days	Measured by polymerase chain reaction
Proportion of target cells killed ex vivo from in vivo generated YF-specific CD8+ T cells	21(+/-3) days	Measured by ex vivo killing assay

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026